Atypical Antipsychotics Influence on the Safety of the Heart and Monitoring Indicators Model Building
Status:
Not yet recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study was to investigate the effect of atypical antipsychotics on cardiac
safety. The secondary purpose was to understand the rate of QTc prolongation in
electrocardiogram induced by atypical antipsychotics. And try to construct the model of
cardiac monitoring index. We conducted a randomized trial in which patients with
schizophrenia who were first on or off medication for more than two weeks took a single
atypical antipsychotic (Risperidone, Aripiprazole, Ziprasidone, Amisulpride, Quetiapine) for
12 weeks and monitored changes in biochemical, electrocardiogram and other indicators. And
then 50 patients with adverse cardiac reactions (ADRs) taking antipsychotics were selected to
review the data, analyze and construct a monitoring model.
We hypothesized that atypical antipsychotics with different mechanisms of action have
different effects on cardiac safety in patients with schizophrenia, and that they are
applicable to different populations. The monitoring index model can reduce the occurrence of
cardiotoxicity and improve the prognosis.